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Abstract
Background: Increasing number of service users diagnosed with schizophrenia and psychosis are being discharged
from specialist secondary care services to primary care, many of whom are prescribed long-term antipsychotics. It is
unclear if General Practitioners (GPs) have the confidence and experience to appropriately review and adjust doses
of antipsychotic medication without secondary care support.
Aim: To explore barriers and facilitators of conducting antipsychotic medication reviews in primary care for
individuals with no specialist mental health input.
Design & setting: Realist review in general practice settings.
Method: A realist review has been conducted to synthesise evidence on antipsychotic medication reviews
conducted in primary care with service users diagnosed with schizophrenia or psychosis. Following initial scoping
searches and discussions with stakeholders, a systematic search and iterative secondary searches were conducted.
Articles were systematically screened and analysed to develop a realist programme theory explaining the contexts
(C) and mechanisms (M) which facilitate or prevent antipsychotic medication reviews (O) in primary care settings,
and the potential outcomes of medication reviews.
Results: Meaningful Antipsychotic medication reviews may not occur for individuals with only primary care medical
input. Several, often mutually reinforcing, mechanisms have been identified as potential barriers to conducting such
reviews, including low expectations of recovery for people with severe mental illness, a perceived lack of capability
to understand and participate in medication reviews, linked with a lack of information shared in appointments
between GPs and Service Users, perceived risk and uncertainty regarding antipsychotic medication and illness
trajectory.
Conclusions: The review identified reciprocal and reinforcing stereotypes affecting both GPs and service users.
Possible mechanisms to counteract these barriers are discussed, including realistic expectations of medication, and
the need for increased information sharing and trust between GPs and service users.
Keywords: Primary care, General practice, Antipsychotic medication, Medication review, Severe mental illness (SMI),
Schizophrenia, Psychosis, Stigma, Trust, Shared decision making (SDM)
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Introduction
People with a diagnosis of schizophrenia or psychosis
are often prescribed long term antipsychotic medication
and treated in specialist secondary care services. How-
ever, people are now increasingly discharged to primary
care and thus no longer have access to specialised care.
In the UK, it is estimated that approximately 30% of
people diagnosed with SMI are under primary care only
[1–3]. Recently, this may have increased further, with
some NHS trusts advising community mental health
teams to discharge as much as 20% of their caseload to
primary care due to the Covid − 19 pandemic.
There is significant literature on shared care agree-
ments between secondary and primary care services to
provide treatment for people with schizophrenia or
psychosis, however little focuses on those people who
are discharged from secondary care. This paper specific-
ally aims to investigate the medication reviews of those
people diagnosed with schizophrenia and/or psychosis,
who no longer receive support from secondary care
services.
In the UK, the Quality and Outcomes Framework re-
quires a yearly health review for those on the SMI regis-
ter, which should include the review of antipsychotic
medication. There is however a paucity of research ex-
ploring the actual processes and content of antipsychotic
medication reviews in primary care. Guidance also rec-
ommends that patients should be “on the lowest possible
dose” [4] to avoid adverse reactions, however it is also
unclear how this is to be achieved in primary care. This
research is important, as studies have indicated that GPs
feel that anti-psychotic medication prescribing is beyond
their remit, and studies report a lack of knowledge and
confidence in prescribing this medication [5]. Audits
have also highlighted issues with current antipsychotic
prescribing, including polypharmacy, dosages above BNF
limits and off-label prescriptions [6, 7].
Antipsychotic medication deserves specific attention,
as it is the main treatment for people with psychosis or
schizophrenia. It is effective in reducing psychotic symp-
toms and reducing the risk of relapse, but it is also asso-
ciated with serious side effects, including sedation and
reduced motivation [8], sudden cardiac death [9], cardio-
vascular disease [10] and possibly decreased brain vol-
ume [11, 12] and cognitive impairment [13]. Although
long-term prescribing has been the norm for decades,
there is also a good rationale to suggest that not every-
one requires long-term treatment or derives more bene-
fit from it than harm [14, 15].
Therefore, antipsychotic medication should be reviewed
regularly and appropriately to ensure that it is prescribed
appropriately. This may be particularly pertinent for pri-
mary care only patients, who are on average older, on
more medication and have been diagnosed for longer than
service users (SU) still under secondary care [2, 3]. Redu-
cing antipsychotic medication should be one of the op-
tions considered, since this has the potential to lower the
risk of cardiovascular events and to reduce immediate side
effects and thus improve quality of life. Such decisions
need to be balanced against risks of relapse and suicide. It
is unclear as to how primary care clinicians should be best
supported in such important decisions. The extent to
which GPs feel they can have discussions about anti-
psychotic medication in this population is unclear, espe-
cially given the lack of guidance available on what
constitutes an appropriate medication review [7, 16].
Aim
The aim of this study is to explore what works, for
whom, how, in what respects, to what extent and in
which contexts, for medication reviews conducted in pri-
mary care for SUs diagnosed with SMI. Specifically, we
explored potential barriers and facilitators to conducting
comprehensive medication reviews from a GP and SU
perspective, for those SU who have been discharged
from secondary care services.
Method
Realist methodology is a theory driven approach, used to
assess complex evidence relating to the implementation
of policy, programmes, services and interventions [17]. It
is concerned with understanding context in relation to
underlying mechanisms of action and aims to address
the key question: what works, for whom, under what cir-
cumstances and how? (as opposed to simply, “does it
work?”) [17]. For this review, the stages outlined by Paw-
son (2006) were followed, as well as the Realist And
Meta-narrative Evidence Syntheses: Evolving Standards
(RAMESES) reporting and quality standards [18, 19].
A realist review was conducted to permit exploration
of the underlying factors which might influence medica-
tion reviews in primary care and the development of a
testable, programme theory, which could guide further
research in this under researched area [17, 20]. This syn-
thesis produced realist ‘context-mechanism-outcome
configurations’ (CMOCs, see Table 1 for Glossary) that
describe and explain the contexts and mechanisms likely
to generate important outcomes relating to antipsychotic
medication reviews [17], including ways to improve pre-
scribing and remove some of the barriers relating to
stigma and stereotypes in clinician and SU interactions,
for those service users who have been discharged from
secondary care.;
The full protocol is available elsewhere (Prospero
CRD42018107573). The stages of the review process
were as follows: 1) focusing the scope, 2) searching for
evidence, 3) document selection, 4) data extraction and
5) data synthesis [17], as illustrated in Fig. 1. At each
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Step, the review processes were informed by discussions
with wider stakeholders: Initially, the authors met with a
member of the local CCG and their primary care mental
health lead on three occasions, and held several conver-
sations throughout the review process with GPs, a GP li-
aison psychiatrist and secondary care psychiatrists. This
review is part of a wider NIHR funded programme – the
RADAR trial on antipsychotic medication reduction. LG,
NC and JM are also affiliated with the RADAR trial [21]
and members of he trial’s LEAP (Lived Experience Ad-
visory Panel), which included mental health service users
and carers, were involved in discussing the initial aims
of the study and reviewing theories on two occasions.
Following these initial discussions, the topic area for
this review was narrowed down based on available evi-
dence, and discussions with the project team, in line
with RAMESES Quality Standard 3 [19]. The review
focus is on GP and primary care only patients’ medica-
tion reviews, leaving out, for example, consideration of
the factors affecting SUs making or attending appoint-
ments, and communication with, or prescribing done
previously in secondary care settings, as these were
Fig. 1 Data sourcing and PT development- Flow Chart
Table 1 Glossary
Term Definition
Attribution Theory a theory which supposes that people attempt to understand the behaviour of others by
attributing feelings, beliefs, and intentions to them [23].
Context (C) Elements outside the parameters of the formal programme architecture, that have causal impact,
e.g. norms and values, economic conditions, participant characteristics
Context Mechanism Outcome Configuration
(CMOC)
Configuration of the contexts, which trigger a mechanism, which results in an outcome.
Diagnostic Overshadowing Misattribution of person’s symptoms as part of their mental health diagnosis rather than a co-
morbid physical health issue. This can lead to incorrect diagnosis and/or delayed treatment.
Mechanism (M) M is the underpinning generative force that leads to outcomes, triggerered by Context
Medication Review In this review, a discussion between GP and SU to discuss the appropriateness and acceptability
of their antipsychotic medication, including side effects, efficacy with regards to mental health
and physical health.
Outcome (O) Any result of a programme or study, can be intended or unintended, expected or unexpected
Programme Theory (PT) A hypothesised theory made up of CMOCs, developed throughout the review (initial programme
theory to refined programme theory)
Realist And MEta-narrative Evidence Syntheses:
Evolving Standards (RAMESES)
Quality and publication standards and training materials for realist research approaches, funded
by the National Institute of Health Research (NIHR) Health Services and Delivery Research
Programmes.
Substantive Theory A higher-level conceptual theory that is not directly about the programme, but introduces a con-
cept(s) that increases the explanatory power of the programme theory
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considered to be out of scope. However, some docu-
ments that included data relating to GP views of second-
ary care were still included, as early discussions
indicated that these views may play a role in the conduct
of medication reviews for primary care only service
users.
For step 2, a systematic search of 11 databases was
conducted to identify studies containing relevant data
for analysis. Two librarians aided the first author in re-
fining the search terms and developing the search strat-
egy. Medline (via HDAS), EMBASE (via HDAS), The
Cochrane Library, CINAHL (via HDAS), PsycINFO (via
HDAS), PsycEXTRA, the Web of Science Core Collec-
tion, Scopus, IBSS, OpenGrey and PubMed (via HDAS)
were searched in August 2018. Search terms included
variations of terms for “antipsychotic medication” and
“primary care”. Initial scoping searches indicated a pau-
city of papers specifically discussing antipsychotic medi-
cation management in primary care settings, so the
search strategy for the main search was designed to
maximise sensitivity, and reduce the risk of missing data
related to any potential contexts or mechanisms (“Big
Bang Approach” [22];. Search results and results from
the initial scoping searches were screened for eligibility
based on the criteria in Table 2. Citation searches were
run in April 2019.
The synthesis of data extracted from documents iden-
tified by the main and citation searches suggested that
stereotypes and stigma were important mechanisms,
therefore one further non-exhaustive, purposive search
was conducted in August 2019 using relevant search
terms to identify additional evidence related to these
mechanisms The full search strategies are available in
additional file 1).
For step 3 (document selection), all papers were
screened by LG, first by title and abstract, and then in
full text, with a 10% random subsample screened in du-
plicate by CD.
All included documents and data were critically ap-
praised and assessed for rigour and relevance [20] in a
2-step process, adapted from Jagosh et al. (2011) and
Francis -Graham et al. (2019) [24, 25]. Please see Add-
itional Files for Template.
1) Overall quality appraisal (Additional Files 2)
assessing the extent to which each document
contributed relevant data (relating to contexts,
mechanisms or outcomes) and assessing each
document for rigour overall (using the Mixed
Methods Appraisal Tool [26] or CASP Systematic
Reviews [27], where possible).
2) Individual CMOC appraisal (Additional File 3)
assessing the set of documents that contributed
data to each CMOC in relation to their relevance to
each CMOC (as each document contributed to
CMOCs to a different extent) and rigour, i.e. the
quality of their contribution to the CMOC (as each
included document may have contributed a
different type of data).
The results of the extraction and quality appraisal
process are detailed in full in the additional files, to pro-
vide transparency with regards to each CMOCs’ evi-
dence base.
For steps 4 and 5 (data extraction and data synthesis),
included documents were read in full and coded by LG,
with a 10% random subsample coded in duplicate by
CD. All included papers from full text screening were
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Adults (age 18 and above) Service users currently under section (Mental Health Act, Forensic, Community Treatment Order)
or currently in crisis or studies discussing Crisis services (Home Treatment Team etc)
Diagnosis of Psychosis, schizophrenia, psychosis
like symptoms (SMI)
Animal studies
Medication reviews, care and treatment of service
users diagnosed with SMI
Physical health reviews only, which do not include factors around treating SU or have
medication reviews alongside
Published after 1954 (year the first antipsychotic
was introduced)
Studies discussing prescription of non-antipsychotic medications
Published in English language Studies from low- and middle-income countries
All study methodologies Studies discussing the prevalence, and treatment of side effects by adding other (non-
antipsychotic) medications
Prescription of antipsychotic medication in primary
care
Studies discussing the prevalence or validity of a diagnosis of severe mental illness
Off – label prescribing
Excluded later:
• Studies investigating bipolar disorder
• Clozapine
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added to NVivo (version 12.6.; qualitative data analysis
software) and were initially coded into descriptive cat-
egories, which could shed light on potential contexts,
mechanisms or outcomes.
Data codes were iteratively refined, and explanatory
CMOCs were developed on the basis of the coded data.
This included several rounds of reading all available doc-
uments and highlighting individual C, M, and O connec-
tions. As the review progressed, it became apparent that
the literature was largely written either from a GP or
from a SU perspective and that the key outcome is
whether medication reviews happen or not, rather than
the content of medication reviews themselves. Therefore,
the data was grouped into “GP perspective” and “SU
perspective” based on data available. The process also in-
cluded extracting data on potential barriers and facilita-
tors, as well as potential alternative outcomes to the
medication review, and data highlighting important con-
texts. Barriers and facilitators were theorised based on
the data available. This included considering contexts or
mechanisms, based on data available, which would coun-
ter act the identified barriers. Further searching was used
to identify additional documents that contained data
used to refine the developing theories, as described
above in step 2. Once all data was were coded, individual
C,M and Os were written on notes and arranged to
allow researchers to develop the final Programme The-
ory (PT).
The process of refining the programme theory involved
retroductive reasoning, based on appraising and juxtapos-
ing data extracted from the included documents. The de-
veloping analysis and explanatory CMOCs were discussed
with stakeholders and refined further on the basis of their
feedback. The CMOCs together allowed formation of an
overall explanatory PT which was tested and refined
throughout the review through these processes of data
triangulation. This included sharing the PT with stake-
holders for feedback and further refinement.
This overall Programme Theory describes identified
barriers and facilitators to discussions about anti-
psychotic medication during GP appointments. Once
the final PT was developed, another round of data ex-
traction was completed to minimise chances of miss-
ing data,
Results
A total of 55 papers were included in this review (for de-
tails, please see Fig. 2 for the literature search results,
Table 3 for a summary of papers identified. A full list of
included papers is available in Additional File 4). No
studies or guidelines directly exploring the needs of GPs
or primary care only SU with respect to antipsychotic
medication were found, despite a comprehensive search,
illustrating the lack of research in this area. In particular,
little evidence was found in relation to facilitators of
antipsychotic medication reviews. As there is lack of re-
search in this area, direct evidence on our population
and setting of interest was unavailable to us. We there-
fore adopted a strategy of ‘borrowing’ data from compar-
able contexts, as is common in realist reviews, supported
by feedback from our stakeholders. We are hypothesis-
ing that some mechanisms which occur in secondary
care may also occur in primary care settings. For ex-
ample, the experience of service users may be the same:
some SUs describe their experience of medication re-
views and/or queries with their GP, but since they were
recruited through secondary care, the locus of care
noted in Table 3 is still secondary care.
The quality of included studies was variable, please see
Additional Files 2 and 3 for assessment of relevance and
rigour for the following results.
Fig. 2 Literature Search
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Initial Programme theory
Following the analysis steps as listed above, including scop-
ing searches and stakeholder meetings, initial programme
theories focused heavily on GPs’ lack of knowledge and
training [28–31], however most SU will know that their GP
has limited training in antipsychotic management and con-
sider that it is more important to be heard and referred at
the right time [32]. Difficulties in adhering to standards
were also noted in physical health [1, 5, 33, 34], suggesting
that a lack of involvement in antipsychotic management
may not simply be related to a lack of mental health know-
ledge and training alone. A lack of mental health guidance
was also considered to be a potentially important factor,
however, even where there was guidance available, it was
not well adhered to, as seen in rates of polypharmacy for
example [7, 35]. Therefore, although GP’s lack of know-
ledge and training are important factors, for the purposes
of this review we focused on other issues.
Other factors, like the low frequency of SMI diagnoses
and complex medication regimes in this population were
excluded from the initial programme theory, as the
former is unamenable to change and the latter is not
specific to SMI diagnoses as GPs tackle complex medi-
cation management in other areas, e.g. pain manage-
ment. Similarly, institutional barriers were considered to
potentially play a role. Stakeholder discussions identified
that GPs cannot easily identify which of their SU are pri-
mary care only, and which are also under secondary
care. Although this is likely to influence the initiation of
conversations about medication, it has excluded as it
represents an administrative barrier that cannot be chan-
ged readily. Following the scoping searches, practice
nurses were also excluded from the review, as they did
not seem involved centrally [3], although there should
be scope for them to be involved as recommended in
the literature [36] and by the LEAP members.
Following the above listed, five step process [17, 20] five
CMOCs were developed, describing potential barriers to
antipsychotic medication reviews in primary care: Table 4
- CMOC Title and Sources
They illustrate potential explanations for a lack of con-
versation about, or appropriate review of antipsychotic
medication in SUs diagnosed with schizophrenia or psych-
osis. Table 3 provides an overview of data included. They
are not mutually exclusive: more than one, or none may
characterise any particular situation, and each may occur
to a lesser or greater extent [81]. These findings are sum-
marised in Table 5 alongside illustrative excerpts of the
data that was used to develop the CMOCs.
Discussion
Summary
This review set out to determine which factors influence
antipsychotic medication reviews in primary care. Using
realist review methodology An extensive search of the
literature identified data that was used to develop several
CMOCs. Taken together, the CMOCs indicate the ways
in which prevalent stereotypes can impede antipsychotic
medication reviews between GPs and SUs. These
include:
1) low expectations of people with SMI and their
recovery resulting in a lack of conversations started
due to hopelessness,
2) the perception that SU lack the capabilities and
“insight” required to manage their illness, leading
SU to feel dismissed and not taken seriously in
appointments.
Table 3 Search results
Source identification 30 articles main search, 20 citation search, 5 iterative searches
Design 34 empirical studies (largely questionnaires and qualitative interviews), 1 systematic review, 16 non-systematic literature
reviews, 4 other
Topic 27 care and treatment of people diagnosed with SMI (of which 10 guidance for GPs, 7 GP surveys on treatment of
people diagnosed with SMI), 21 experience of taking antipsychotics from SU perspective, 7 stigma and Shared
Decision Making
Country 31 = UK, 10 = USA, 7 = Australia, 3 = Canada, 1 = Ireland, 1 = Italy, 1 = Israel, 1 = Switzerland, 1 = Austria
Locus of care 23 = primary care, 5 = secondary care, 26 = about care or treatment in general, without specifically looking at service
provision in secondary or primary care services, 2 = n/a - setting unrelated to mental health
Table 4 CMOC Title and Sources
CMOC Title Source Data used
1. Low expectations regarding recovery from mental illness [1, 5, 30–32, 34, 37–60]
2. Perceived lack of SUs’ capabilities to participate in medication reviews [1, 7, 23, 32, 37, 39, 44–46, 52, 54, 55, 58, 60–69]
3. Lack of information sharing between GPs and SU [1, 5, 29, 33, 37, 43–45, 47, 54, 60, 63, 65, 66, 69–74]
4. Perceived risk of SUs [23, 30, 39, 41–43, 47, 53, 54, 58, 59, 75–79]
5. Mutual uncertainty regarding medication and illness trajectory [1, 4, 5, 43, 48, 49, 52, 55, 60, 66, 76, 80]
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Table 5 Barriers and facilitators to antipsychotic medication reviews
Barriers Group CMOC Key quote Facilitator
1. Low
expectations
GP Where GPs have low expectations
regarding recovery for SU diagnosed
with SMI(C), and rely on antipsychotics
as a main treatment (C), then they may
be left feeling hopeless (M), leading to
little or no ongoing antipsychotic
medication reviews (O).
“the most significant obstacles to the
effective management of the
chronically mentally ill are the
prevailing negative attitudes and
believes about them” [56] - author
Realistic expectations of what the
medication can achieve [43, 62, 66],




Where GPs communicate hopelessness
to SU (C), they may in turn feel
hopeless (M), and therefore unlikely to
commence a conversation about
medication(O).
“When I approached my GP, he [..] said,
‘Well, you’ll be on these tablets for the
rest of your life,[…] being told I’d never
be able to work again, I’d never have
an education, never have relationships,
never have anything in my life. So, for a
period of time I thought well, there’s
no hope” [32] – SU focus group




GP Where GPs perceive SUs to lack
capabilities and/ or “insight” (C), despite
years of stability (C), GPs may act in a
paternalistic/authoritarian way (M) and
dismiss medication queries (O) and a
conversation regarding medication(O).
Additional Context:
1) Where antipsychotic side effects are
apparent in SU (apathy, cognitive
impairment)
2) Where GPs feel pressure to prescribe
3) Diagnostic overshadowing (see
Glossary)
GPs scepticism towards reliability and
insight of people with psychosis may
discourage clients themselves from
help-seeking, with further negative
effects on their health” [59] – author
“I’ve had difficulty in getting full regular
medical check-ups as every symptom is
considered a sign for stress” [47] -SU
interviews
See SU as capable; enable SU to
discuss medication/ side effects;
notion that medication queries are
justified [43, 44, 82, 83]
Commitment to Shared Decision
Making (O)
SU In turn, experiencing a dismissal of their
queries (C), particularly if SUs have a
history of being coerced to take
medication or being committed to
treatment against their will (sectioning)
(C), this will lead to decreased trust (M)
in GPs, leading SU to not discuss
medication with their GP (O) and covert
medication changes (O).
I think it’s just a general disregard for
they have for anything that people say,
because they’re mentally ill therefore
you know, anything they say is
questionable [..] and they say, well, I
have a problem with chlorpromazine or
something, they might override that,
rather than listen to what the consumer
is saying” [84] – SU interview
Feel listened to, taken seriously, time




SU Information about medication:
Due to a lack of information (C), SU
may be unaware (M) of the risk
associated with antipsychotics and the
need for check-ups, leading to no
conversation (O) and lack of attendance
at reviews (O).
55% [of patients] said that they were
unaware of the potential metabolic
side-effects of atypical antipsychotic
medications [..]61% said that they had
had no monitoring blood tests in the
past year. 69% did not know that
certain monitoring blood tests were
recommended [33]. – SU response to
survey
Provide more information [33, 43, 63,
71, 85]. Research required to
established what constitutes
sufficient information.
GP Information about side effects:
Where GPs are aware of side effects (C),
they may fear (M) that SU will
discontinue their medication (O) and
feel it is in the SUs interest (M) to not
share more information regarding side
effects (O).
“At one time … it was … if you tell
patients about side effects, they won’t
take the medication.” [74] – pharmacist
interview
Increased information sharing can
lead to higher adherence and
facilitates trust [60, 84]
SU Due to lack of discussion about side
effects (C), SU may in turn feel shocked
(M) and loss of trust (M), where they
experience side effects (C) which may
lead them to alter or discontinue
medication without further consultation
(O).
Distrust (M) is potentially amplified
when SU access information elsewhere
(C), like the internet, and realise that
those are potentially common side
effects.
“Lack of communication about
antipsychotics was the contributing
factor to my stopping attempt. I recall
vividly when I was sitting on the couch,
watching TV, and I looked down and I
noticed my chest was wet, upon further
inspection I realized that I was lactating.
I was shocked, scared, and terrified. It
was at that moment that I decided to
quit.” [63]– SU interview
Access to sufficient information
could help to increase SU confidence
to commence conversations about
medication [61]
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3) a lack of information from both GPs and SU. GPs
may not share sufficient information regarding
medication risks and side effects due to fears of SU
stopping medication. Equally, SU may not share all
information regarding their current dose and
symptoms due to fears of coercion and sectioning.
4) the perception that SU pose a risk, preventing a
trusting GP – SU relationship to from forming and
5) mutual understandable concerns regarding
antipsychotic medication changes, due to the
potential for relapse and uncertainties regarding
effects of dose reduction, resulting in avoidance of
reviewing antipsychotic medication.
Attribution theory as substantive theory
The evidence reviewed suggested several factors that are
relevant to whether appropriate medication reviews are
conducted with individuals with schizophrenia or psych-
osis. Firstly, it identified a lack of communication be-
tween SU and GPs in relation to antipsychotic
medication. Attribution theory, as substantive theory, of-
fers a useful lens to better understand and explain the
effect of these stereotypes, and potentially suggest how
their effects may be reduced [23]. Attribution theory
suggests that stereotypes held by clinicians and SU can
change their behaviour towards each other [23, 86].
Corrigan proposes that “signals” like the label of “severe
Table 5 Barriers and facilitators to antipsychotic medication reviews (Continued)
Barriers Group CMOC Key quote Facilitator
4.Perceived
risk
GP Despite evidence to the contrary, GPs
may consider SUs to be a risk to others
(C), which can lead to fear in GPs (M),
which may then lead to avoidance of
medication reviews (O), or GPs taking a
passive role (O).
A survey of GP attitudes to people
diagnosed with schizophrenia found
that they endorsed either “partially true”
or “completely true” for: “people are
frightened by them (93.9%) and ‘they
would become dangerous if they
stopped their medication’ (73.9%) [59].–
GP responses to survey
A survey of provider ratings of
metabolic care barriers found that the
most endorsed item in the category
“primary care provider barriers” is
“providers are scared of people with
SMI” [76]– clinician responses to survey
Research needed to explore how to
increase GPs feeling safe in
appointments.
SU Where SUs have current/previous
experience of being perceived as
frightening (C), a good GP-SU
relationship or open conversation is
unlikely to occur (O).
We were unable to elicit a mechanism
here. Mechanisms were not identified
in the literature, it is possible that a loss
of trust or feeling disillusioned could
play a role, however further research is
required.
SU “felt their GP was scared of them,
ending a consultation quickly and
suggesting they find a different GP” [47]
– SU interview
Feel comfortable at their GP practice,







GP Where there is a lack of guidance and
(perceived) secondary care support (C),
GPs may worry (M) about relapses and
lack confidence (M) in changing
medication and then they may be
reluctant to change medication (O)
even where SU are stable in mental
health (C).
Many GPs are reluctant to reduce these
without supervision, especially when
the patient appears well. […] There is
no clear agreement on the optimum
frequency for reviewing maintenance
treatment, nor is there consensus on
what symptom-free period warrants
consideration of discontinuation [1]. -
author
Guidance on how to review and
reduce (if indicated), secondary care
support [1, 43]
SU SU may feel equally concerned (M) to
start a conversation about medication
(O), due to fears of relapse (M),
especially for those who have a history
of sectioning (C). SU may not even be
aware that medication changes are
possible (C)
“This dynamic [power imbalance]
resulted in some participants feeling
coerced into taking medication and out
of control. [..]When the option to
discontinue neuroleptic medication was
not explicit, participants were left with
uncertainty regarding the level of
support they could expect from
clinicians. […] All participants
acknowledged the risks of withdrawing
neuroleptic medication [43]. - SU
interviews
Continuity of care; building of
trusting relationship to enable
discussion of medication changes
and to identify and manage
potential relapse [54, 60, 82]
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mental illness” and perceived skill deficits of mental ill-
ness can lead to a range of stereotypes, like authoritar-
ianism and paternalism, which lead to discriminatory
behaviour with regards to housing, employment and
treatment. GP expectations of lack of capacity or
“insight” for example can lead to paternalistic attitudes,
which prevent properly informed discussions about
treatment, and do not facilitate participation of the indi-
vidual in the decision-making process. The review find-
ings evidence this, as well as the need for aspects of the
therapeutic relationship, like hope and trust, to counter
some of those mechanisms.
Recommendations
Using the findings above, the following recommendations
can be made (Fig. 3). In order to counteract some of the
mechanisms listed above, mainly hopelessness and mis-
trust, the following contexts have been identified as poten-
tially counteracting the mechanism.
Increased trust has been associated with a better thera-
peutic alliance [43, 54, 60, 61, 82]. Given that there are
multiple types of antipsychotics and dosing options,
varying responses to antipsychotic medication, and no
guidelines on how to review and reduce medication [16],
GPs and SU encounter many uncertainties. Managing
these uncertainties together requires a trusting relation-
ship between GP and SU [60, 61]. Any history of coer-
cion or sectioning under the Mental Health Act can
make developing and maintaining trust more difficult,
but a trusting relationship is key to shared decision mak-
ing [29, 82]. Given the power imbalance between SU
and GPs, and often held view that “doctor knows best”
[82] the onus might be on the GP to start the
conversation.
Strength and limitations
This review has benefited from the input of a diverse
stakeholder group, including GPs, psychiatrists, and a
Lived Experience Advisory panel (LEAP). This input
helped ensure that the views of these groups informed the
focus of the review, and the development and refinement
of the programme theory. The data included in this review
Fig. 3 Recommendations
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was found in documents identified by a comprehensive lit-
erature search strategy, including sensitive searches in a
wide range of databases and the inclusion of additional
material via citation chaining. The review has been con-
ducted and reported following the RAMESES standards
[18, 19]. Conducting the review based on these guidelines
included focusing the topic of the review, meaning that
not every facilitator and barrier was covered in this review.
Future research should address this.
The review’s findings are limited by the availability of
data used to develop the CMOCs presented above. For ex-
ample, no CMOCs were identified in relation to balancing
risks of reducing versus continuing medication, or in rela-
tion to best methods for tapering medication when this is
indicated, highlighting the need for further research in this
area. The review identified little data on the involvement
of other health professions, including pharmacists, in anti-
psychotic medication reviews. Future research should ex-
plore this role. Due to paucity of research, including
pharmacists and nurses in stakeholder groups could help
shed light on this.
Many of the included studies focused on specific con-
texts and outcomes, providing little data relating to
mechanisms, or on why the outcomes they included
were found. Although several included studies addressed
the care of SU with a diagnosis of schizophrenia or
psychosis in primary care specifically, none have
researched a primary care only population. As a result,
the findings are applied with caution to this population.
This review should be viewed as an initial model,
which has identified several CMOCs which require fur-
ther testing and refinement, eg.it is possible that there
are additional C, M or Os not identified in this review.
The review also has a UK focus, and some findings
may not apply to countries where GPs do not act as
“gate-keepers” to secondary or specialist care.
Comparison with existing literature
The review did not identify any existing literature, prac-
tice guidelines or interventions assessing the treatment
and care of SU who are under primary care only. Previ-
ous research found that when comparing patient re-
cords, primary care only SU are older, have fewer GP
appointments and are on more medication overall [2, 3].
The content of antipsychotic medication reviews, as well
as their feasibility in primary care, have not been investi-
gated. A focus group study of SU diagnosed with SMI
was conducted in primary care [32], however SU were
not explicitly primary care only, therefore it is difficult
to estimate their treatment experiences and expectations
of their interaction with GPs, since they may differ if
they are no longer under secondary care. A recent sys-
tematic review also identified expectations of low cap-
abilities, lack of trust and paternalism (including the
decision to limit the amount of information regarding
adverse effects shared and “doctor knows best” mentality
[87];) as barriers to patient involved prescribing.
Previous literature cites negative symptoms like apathy
and paranoia, as well as cognitive difficulties associated
with a diagnosis of SMI, as a reason for lack of engage-
ment with health services in this population [5, 83]. The
above listed CMOCs offer additional explanations,
alongside potential solutions to improve engagement in
the future. A recent study on lifestyle interventions to
reduce cardiovascular risk also found that primary care
health professionals described people diagnosed with
schizophrenia/psychosis as “threatening or scary or diffi-
cult” (p7), [88]. This prevented staff from offering inter-
ventions. These results align with the findings of this
review and illustrate the impact stigma still has on ser-
vice provision. Clearer guidance is needed to address is-
sues around (perceived) risk management in this
population.
Implications for research and/or practice
More research is urgently needed to address this gap in
knowledge regarding the needs of people who are cur-
rently only seen in primary care. Future research should
address how GPs can be better supported to look after a
population estimated to include approximately 30% of
all SU with a diagnosis of schizophrenia or psychosis [2,
3]. This research should include studies linking patient-
level data from primary care with secondary care patient
records, to establish exact numbers of primary care only
SUs, and compare the demographics and potentially
unique needs of this population. Research should also
explore SU and GP views on receiving or providing anti-
psychotic medication reviews solely in primary care. Sev-
eral recommendations for practice can be made on the
basis of this review’s findings. Increasing GP knowledge
regarding antipsychotic treatment could help GPs to de-
velop their confidence to balance risks and benefits and
make changes to medication, like reducing doses to im-
prove side effect burden. Greater familiarity with the re-
covery agenda may help GPs to appreciate the
possibilities of living a fulfilling life with and without
medication, to counter some of the hopelessness identi-
fied in CMOC 1.
To combat some communication difficulties (as seen
in CMOC 2), GPs need to enable SU to express their
views [82, 83] and take SU concerns seriously [44]. This
may also include structured assessments, as SU may not
volunteer problems with their medication [2]. SU com-
plaints and queries regarding antipsychotic medication
should be assumed to be justified and need proper con-
sideration. Such ways of working are established best
practice in consultation in primary care [89] but may be
less common when working with individuals with
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psychosis. Conversations about medication should in-
clude sufficient information about antipsychotic medica-
tion (CMOC 3), and side effects as well as benefits.
Increasing SU awareness of potentially severe side effects
has been associated with increased trust between SU and
GP [60, 82] and allows SU to prepare for side effects and
return to the GP for help if they persist or cause prob-
lems. Research is needed to determine what constitutes
“sufficient” information, as most data identified for this
review only refers to a “lack of information” without spe-
cifying what additional information would be required.
Engagement with physical health monitoring may also in-
crease, if SU are aware of the specific reasons for this
(CMOC 3), which may tackle some health disparities be-
tween this population and the general population [70]. This
may also help to avoid SU discontinuing medication without
consultation. Some evidence suggests that pharmacists can
help to increase knowledge [74, 84]. This could ease the pres-
sure of time limited appointments. Access to sufficient infor-
mation could help to increase SU confidence to commence
conversations about medication [61], improve adherence [66,
72], patient safety [76] and facilitate Shared Decision Making
(SDM [62];). A more nuanced knowledge of risk would be
beneficial (CMOC 4). Whereas there are certain risks associ-
ated with a SMI diagnosis, like higher rates of substances
abuse, these are not as great as perceived by the general
population [58], and SU have been found to be 14 times
more likely to be victims of violent crime than being the per-
petrator [90]. A safe environment needs to be developed for
GPs and SU alike.
Concerns about relapse are understandable (CMOC 5)
but should not necessarily exclude attempts to reduce
the dose of antipsychotic medication slowly and carefully
to facilitate patient choice and minimise side effects and
health complications. GPs may require support from
secondary care for such an approach, however, and
smoother liaison between primary and secondary care
might be needed to facilitate this. Continuity of care has
been highlighted as a crucial factor for this population
[54, 82] as it can help GPs to potentially spot signs of re-
lapse early and offer appropriate support, and is likely to
be an important factor in facilitating a safe process of
medication change. Continuity may also increase SU
trust and encourage the start of conversations about
medication. Trust could also facilitate safer prescribing
[60], as SU may tailor their dose of medication, without
necessarily consulting their doctor [84] and may be re-
luctant to disclose this due to fears of being sectioned/
coerced.
Better guidance on safe reduction and discontinuation
of medication [16], with a specific focus on whether this is
achievable in primary care is needed, as well as better links
between primary and secondary care services, as GPs do
not seem to feel supported [5, 31, 91, 92]. Knowing that
support is available may increase GP confidence. Alterna-
tively, SU could be referred back to secondary psychiatric
services for periodic reviews of and recommendations
about their medication regimes.
This review has developed a testable programme theory
highlighting the role of hope and trust in improving anti-
psychotic medication reviews for people diagnosed with
schizophrenia and/or psychosis. Piloting and evaluating these
recommendations further could be a start to strengthening
trust and commencing conversations, to enable appropriate
and safe prescribing, whilst also maximising quality of life.
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